COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV • FR0000064578

59.35 EUR
+0.6 (+1.02%)
Last: Feb 20, 2026, 07:00 PM
Fundamental Rating

3

COV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 41 industry peers in the Diversified REITs industry. While COV is still in line with the averages on profitability rating, there are concerns on its financial health. While showing a medium growth rate, COV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year COV was profitable.
  • In the past year COV had a positive cash flow from operations.
  • Of the past 5 years COV 4 years were profitable.
  • Each year in the past 5 years COV had a positive operating cash flow.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

  • With a Return On Assets value of 1.63%, COV perfoms like the industry average, outperforming 46.34% of the companies in the same industry.
  • COV has a Return On Equity of 5.08%. This is comparable to the rest of the industry: COV outperforms 56.10% of its industry peers.
  • The Return On Invested Capital of COV (3.21%) is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for COV is in line with the industry average of 3.45%.
  • The 3 year average ROIC (2.97%) for COV is below the current ROIC(3.21%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

  • With a Profit Margin value of 30.43%, COV perfoms like the industry average, outperforming 46.34% of the companies in the same industry.
  • In the last couple of years the Profit Margin of COV has declined.
  • COV has a Operating Margin of 57.80%. This is in the lower half of the industry: COV underperforms 63.41% of its industry peers.
  • COV's Operating Margin has been stable in the last couple of years.
  • COV has a Gross Margin (74.42%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 57.8%
PM (TTM) 30.43%
GM 74.42%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COV is destroying value.
  • COV has more shares outstanding than it did 1 year ago.
  • COV has more shares outstanding than it did 5 years ago.
  • COV has a better debt/assets ratio than last year.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • COV has an Altman-Z score of 0.54. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.54, COV is doing worse than 73.17% of the companies in the same industry.
  • The Debt to FCF ratio of COV is 28.49, which is on the high side as it means it would take COV, 28.49 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of COV (28.49) is worse than 70.73% of its industry peers.
  • COV has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
  • COV has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: COV underperforms 78.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.54
ROIC/WACC0.54
WACC5.89%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • COV has a Current Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a Current ratio of 0.76. This is in the better half of the industry: COV outperforms 68.29% of its industry peers.
  • A Quick Ratio of 0.69 indicates that COV may have some problems paying its short term obligations.
  • The Quick ratio of COV (0.69) is better than 65.85% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

  • COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.98%.
  • The Earnings Per Share has been decreasing by -3.39% on average over the past years.
  • COV shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.96%.
  • The Revenue has been growing slightly by 1.17% on average over the past years.
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%

3.2 Future

  • Based on estimates for the next years, COV will show a small growth in Earnings Per Share. The EPS will grow by 3.53% on average per year.
  • The Revenue is expected to grow by 4.10% on average over the next years.
EPS Next Y5.02%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
EPS Next 5YN/A
Revenue Next Year1.77%
Revenue Next 2Y3.17%
Revenue Next 3Y4.1%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.87, the valuation of COV can be described as correct.
  • 65.85% of the companies in the same industry are more expensive than COV, based on the Price/Earnings ratio.
  • COV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • The Price/Forward Earnings ratio is 12.42, which indicates a correct valuation of COV.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of COV is on the same level as its industry peers.
  • COV is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.87
Fwd PE 12.42
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • COV's Enterprise Value to EBITDA is on the same level as the industry average.
  • Based on the Price/Free Cash Flow ratio, COV is valued a bit more expensive than 68.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.87
EV/EBITDA 17.36
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates COV does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.57
PEG (5Y)N/A
EPS Next 2Y3.41%
EPS Next 3Y3.53%

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.38%, COV is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 5.41, COV pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.38%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • 92.86% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.86%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (2/20/2026, 7:00:00 PM)

59.35

+0.6 (+1.02%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-20
Inst Owners42.11%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.62B
Revenue(TTM)1.37B
Net Income(TTM)417.40M
Analysts75
Price Target63.81 (7.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.38%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.86%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.39%
PT rev (3m)-0.96%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.04%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.88%
Valuation
Industry RankSector Rank
PE 12.87
Fwd PE 12.42
P/S 4.83
P/FCF 16.87
P/OCF 6.6
P/B 0.81
P/tB 0.84
EV/EBITDA 17.36
EPS(TTM)4.61
EY7.77%
EPS(NY)4.78
Fwd EY8.05%
FCF(TTM)3.52
FCFY5.93%
OCF(TTM)8.99
OCFY15.15%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)2.57
PEG (5Y)N/A
Graham Number87.41
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.8%
PM (TTM) 30.43%
GM 74.42%
FCFM 28.62%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexgc growth 3Y12.16%
ROICexgc growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.78%
Profit Quality 94.06%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.54
F-Score7
WACC5.89%
ROIC/WACC0.54
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
EPS Next Y5.02%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
EPS Next 5YN/A
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%
Revenue Next Year1.77%
Revenue Next 2Y3.17%
Revenue Next 3Y4.1%
Revenue Next 5YN/A
EBIT growth 1Y-0.75%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year12.83%
EBIT Next 3Y8.07%
EBIT Next 5Y7.52%
FCF growth 1Y41.8%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y30.51%
OCF growth 3Y12.5%
OCF growth 5Y4.86%

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 3 / 10 to COVIVIO (COV.PA). This can be considered as Overvalued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the financial health of COVIVIO (COV.PA) stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


How sustainable is the dividend of COVIVIO (COV.PA) stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.86%.